http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Andy Bass to Lead Biological & Popular Culture, Intrexon's Consumer Sector
-
Intrexon Announces Fourth Quarter and Full Year 2016 Financial Results
-
Fibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa
-
Intrexon to Announce Fourth Quarter and Full Year 2016 Financial Results on March 1st
-
Lt. Gen. (Ret.) Thomas P. Bostick, Head of Intrexon's Environment Sector, Elected to National Academy of Engineering
-
Exemplar Genetics Awarded Subcontract to Advance New Therapeutic Models for Sickle Cell Disease
-
Intrexon (XON) to Acquire GenVec (GNVC)
-
Intrexon to Acquire GenVec to Expand Industry-Leading Gene Delivery Platform
-
Oxitec and GBIT Announce Launch of Friendly™ Aedes Project in India
-
Intrexon (XON) Announces "When-Issued" Trading of Spin-Off AquaBounty (AQB)
-
Intrexon Announces "When-Issued" Trading of AquaBounty Technologies In Connection With Special Stock Dividend of Shares
-
ZIOPHARM and Intrexon Announce Cooperative Research and Development Agreement with the National Cancer Institute Utilizing Sleeping Beauty System to Generate T cells Targeting Neoantigens
-
Fibrocell Science (FCSC) Receives FDA Fast Track Designation of FCX-007 for Treatment of RDEB
-
Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
-
Intrexon to Present at the 35th Annual J.P. Morgan Healthcare Conference
-
Intrexon (XON) Announces Special Stock Dividend of AquaBounty Technologies Shares
-
Intrexon Announces a Special Stock Dividend of Shares of AquaBounty Technologies
-
Fibrocell Announces Leadership Changes
-
Intrexon (XON) Advances ActoBiotics to Development Phase
-
Intrexon Advances ActoBiotics™ Platform to Development Phase for Biological Crop Protection
-
Oxitec's Medfly Ready for Open Field Trials
-
Oxitec Announces Friendly™ Aedes Project is Supported By 92.8% of Piracicaba’s Population
-
Oxitec Announces FKMCD Approval of Self-Limiting Friendly Use (XON)
-
Board of Florida Keys Mosquito Control District Approves Investigational Agreement for Effectiveness Trial of Oxitec's Friendly™ Mosquitoes in Monroe County, Florida
-
Intrexon to Present at the Stifel 2016 Healthcare Conference
-
Fibrocell Science (FCSC) Names New Chief Medical Advisor
-
Fibrocell Appoints Alfred T. Lane, MD, Chief Medical Advisor
-
Intrexon Announces Third Quarter 2016 Financial Results
-
Intrexon (XON) Announces Monroe County Votes in Support of Trial Utilizing Oxitec's Genetically Engineered Mosquitoes
-
Monroe County Votes in Support of Florida Keys Mosquito Control District Conducting an Effectiveness Trial Utilizing Oxitec’s Genetically Engineered Mosquitoes
-
Fibrocell Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
-
Intrexon to Announce Third Quarter 2016 Financial Results on November 9th
-
Fibrocell to Host Conference Call and Webcast on Thursday, November 3, 2016 to Discuss Third Quarter 2016 Financial Results and Recent Operational Highlights
-
Intrexon's (XON) Oxitec Large Mosquito Production Facility in Brazil
-
Oxitec Opens Large Scale Mosquito Production Facility in Brazil
-
Fibrocell to Present at 2016 Cell & Gene Meeting on the Mesa
-
Intrexon Grants Employment Inducement Award Pursuant to NYSE Rule 303A.08
-
Lieutenant General (Ret.) Thomas P. Bostick to Lead Intrexon's Environment Sector
-
Intrexon (XON) Unit Receives USDA Approval for Arctic Fuji Apple
-
Arctic® Fuji Gains USDA Approval
-
Intrexon (XON) Enters into Exclusive Channel Collaborations with Two Startups
-
Intrexon to Develop Disease-Modifying Therapies in New Collaborations with Harvest Intrexon Enterprise Fund
-
Fibrocell Science (FCSC) Completes Enrollment in NC1+ Cohort of Phase I/II Clinical Trial of FCX-007 to Treat RDEB
-
Fibrocell Completes Enrollment in NC1+ Cohort of Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
-
Intrexon (XON) Announces Florida Request for Emergency Authorization to Combat Mosquitoes
-
Florida Speaker-Designate and House Members Request Emergency Authorization to Combat Aedes aegypti Mosquitoes with Oxitec Technology
-
Florida Speaker-Designate and House Members Request Emergency Authorization to Combat Aedes aegypti Mosquitoes with Oxitec Technology
-
Oxitec and Piracicaba City Hall Start Release of Friendly™ Aedes
-
Intrexon Announces Second Quarter and First Half 2016 Financial Results
-
Fibrocell Announces Proposed Public Offering of Common Stock and Warrants

